Loading…
SILO
Silo Pharma, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 82711P300
$2.540.00%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.45M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$3.71
- ROE
- -91.23%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.80
- 52-week high
- $15.15
- 52-week low
- $2.43
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.8% over 5Y.
today you would have $11.97▼ -98.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.10 | $13.35 | $21.60 | $50.40 | |
| P/S | 60.4x | 62.8x | 55.4x | 58.0x | 147.2x |
| P/B | 0.8x | 0.7x | 0.8x | 0.7x | 1.0x |
| EPS | -$7.50 | -$17.85 | -$18.00 | -$25.65 | |
| Profit margin | -5642.18% | -5863.50% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SBFMSunshine Biopharma Inc. | $1.15 | — | 0.0x | — | -21.92% | $4.46M |
| XAIRBeyond Air, Inc. | $4.48 | 0.0x | 0.4x | — | -519.51% | $4.41M |
| VVOSVivos Therapeutics, Inc. | $0.22 | — | — | — | -8585.26% | $4.52M |
| ELABPMGC Holdings Inc. | $5.31 |
About the company
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- 3
- Sarasota, United States
Company description provided by Yahoo Finance.